BIOMAT Database Logo BIOMAT Database Logo

Phase I study of doxorubicin, ICRF-187 and granulocyte/macrophage-colony-stimulating factor. 1992

C Walsh, and R H Blum, and R Oratz, and A Goldenberg, and A Downey, and J L Speyer
Kaplan Cancer Center, New York University Medical Center 10016.

A group of 16 patients with advanced malignancy were entered on a phase I trial of escalating doses of doxorubicin with ICRF-187 for cardioprotection and granulocyte/macrophage-colony-stimulating factor (GMCSF) for bone marrow protection. Patients received intravenous ICRF-187 (dose ratio 20:1 ICRF-187:doxorubicin) 30 min prior to doxorubicin. GMCSF at a dose of 15 micrograms kg-1 day-1 was self-administered subcutaneously on days 3-14 of the cycle. Doxorubicin was administered every 21 days. Substantial hematological and non-hematological toxicity was seen. Fever, malaise, and pulmonary symptoms, thought to be due to GMCSF, were not eliminated by reduction in the GMCSF dose to 10 or 5 micrograms kg-1 day-1. Severe hematological toxicity was seen despite GMCSF administration and it was not possible to escalate the doxorubicin dose above 72 mg/m2 with this combination. Dose escalation of doxorubicin may be more feasible with the use of other growth factors or growth factor combinations.

UI MeSH Term Description Entries
D008297 Male Males
D009369 Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms. Benign Neoplasm,Cancer,Malignant Neoplasm,Tumor,Tumors,Benign Neoplasms,Malignancy,Malignant Neoplasms,Neoplasia,Neoplasm,Neoplasms, Benign,Cancers,Malignancies,Neoplasias,Neoplasm, Benign,Neoplasm, Malignant,Neoplasms, Malignant
D011929 Razoxane An antimitotic agent with immunosuppressive properties. ICRF-159,ICRF-186,NSC-129943,Razoxane Mesylate, (R)-Isomer,Razoxane, (R)-Isomer,Razoxin,ICRF 159,ICRF 186,ICRF159,ICRF186,NSC 129943,NSC129943
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D004317 Doxorubicin Antineoplastic antibiotic obtained from Streptomyces peucetius. It is a hydroxy derivative of DAUNORUBICIN. Adriamycin,Adriablastin,Adriablastine,Adriblastin,Adriblastina,Adriblastine,Adrimedac,DOXO-cell,Doxolem,Doxorubicin Hexal,Doxorubicin Hydrochloride,Doxorubicin NC,Doxorubicina Ferrer Farm,Doxorubicina Funk,Doxorubicina Tedec,Doxorubicine Baxter,Doxotec,Farmiblastina,Myocet,Onkodox,Ribodoxo,Rubex,Urokit Doxo-cell,DOXO cell,Hydrochloride, Doxorubicin,Urokit Doxo cell
D004341 Drug Evaluation Any process by which toxicity, metabolism, absorption, elimination, preferred route of administration, safe dosage range, etc., for a drug or group of drugs is determined through clinical assessment in humans or veterinary animals. Evaluation Studies, Drug,Drug Evaluation Studies,Drug Evaluation Study,Drug Evaluations,Evaluation Study, Drug,Evaluation, Drug,Evaluations, Drug,Studies, Drug Evaluation,Study, Drug Evaluation
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D016178 Granulocyte-Macrophage Colony-Stimulating Factor An acidic glycoprotein of MW 23 kDa with internal disulfide bonds. The protein is produced in response to a number of inflammatory mediators by mesenchymal cells present in the hemopoietic environment and at peripheral sites of inflammation. GM-CSF is able to stimulate the production of neutrophilic granulocytes, macrophages, and mixed granulocyte-macrophage colonies from bone marrow cells and can stimulate the formation of eosinophil colonies from fetal liver progenitor cells. GM-CSF can also stimulate some functional activities in mature granulocytes and macrophages. CSF-GM,Colony-Stimulating Factor, Granulocyte-Macrophage,GM-CSF,Histamine-Producing Cell-Stimulating Factor,CSF-2,TC-GM-CSF,Tumor-Cell Human GM Colony-Stimulating Factor,Cell-Stimulating Factor, Histamine-Producing,Colony Stimulating Factor, Granulocyte Macrophage,Granulocyte Macrophage Colony Stimulating Factor,Histamine Producing Cell Stimulating Factor,Tumor Cell Human GM Colony Stimulating Factor

Related Publications

C Walsh, and R H Blum, and R Oratz, and A Goldenberg, and A Downey, and J L Speyer
Phase I study of recombinant DNA granulocyte macrophage colony stimulating factor.
August 1988, Behring Institute Mitteilungen,
C Walsh, and R H Blum, and R Oratz, and A Goldenberg, and A Downey, and J L Speyer
Granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor (1).
July 1992, The New England journal of medicine,
C Walsh, and R H Blum, and R Oratz, and A Goldenberg, and A Downey, and J L Speyer
Granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor (2).
July 1992, The New England journal of medicine,
C Walsh, and R H Blum, and R Oratz, and A Goldenberg, and A Downey, and J L Speyer
Phase I/II study of combined granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor administration for the mobilization of hematopoietic progenitor cells.
January 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
C Walsh, and R H Blum, and R Oratz, and A Goldenberg, and A Downey, and J L Speyer
Granulocyte-macrophage colony-stimulating factor.
January 1990, Immunology series,
C Walsh, and R H Blum, and R Oratz, and A Goldenberg, and A Downey, and J L Speyer
Granulocyte-macrophage colony-stimulating factor.
January 1990, Biotherapy (Dordrecht, Netherlands),
C Walsh, and R H Blum, and R Oratz, and A Goldenberg, and A Downey, and J L Speyer
[Granulocyte-macrophage colony-stimulating factor].
July 2010, Nihon rinsho. Japanese journal of clinical medicine,
C Walsh, and R H Blum, and R Oratz, and A Goldenberg, and A Downey, and J L Speyer
[Granulocyte-macrophage colony-stimulating factor].
August 2005, Nihon rinsho. Japanese journal of clinical medicine,
C Walsh, and R H Blum, and R Oratz, and A Goldenberg, and A Downey, and J L Speyer
Granulocyte-macrophage colony-stimulating factor.
July 1991, Journal of pediatric oncology nursing : official journal of the Association of Pediatric Oncology Nurses,
C Walsh, and R H Blum, and R Oratz, and A Goldenberg, and A Downey, and J L Speyer
Granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor: double-edged swords.
November 2005, Journal of the American College of Cardiology,
Copied contents to your clipboard!